December 29, 2011 — A budesonide/formoterol pressurized metered dose inhaler (pMDI) reduced chronic obstructive pulmonary disease (COPD) exacerbations more effectively than a formoterol dry powder ...
Health professionals tasked with advising patients with asthma and chronic obstructive pulmonary disease (COPD) how to use inhaler devices properly and what to do about unwanted effects will be aware ...
23RD MARCH 2026: Kindeva, a global CDMO and drug delivery innovator, commemorates 70 years today, since the invention of the pressurized metered dose inhaler (pMDI), a breakthrough therapy that ...
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ...
Market leader in respiratory innovation highlights potentially harmful[1] consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they ...
AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...
Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...
If you're having an asthma attack, you assume that with each puff of your inhaler you are getting relief. But, in many cases, it seems inhalers are being used long after they have run out of ...
New York, March 21, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Respiratory Inhalers Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results